Site search
2898 results for '' found
Randomized,Embedded,Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) (NCT02735707)
Randomized,Embedded,Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) (NCT02735707)
/
A prospective, double-blinded, randomised study comparing 16g automated full-core and side-notch biopsy needles for percutaneous renal biopsies in renal transplant patients (Trial Not Registered)
A prospective, double-blinded, randomised study comparing 16g automated full-core and side-notch biopsy needles for percutaneous renal biopsies in renal transplant patients (Trial Not Registered)
/
A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previo
A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previo
/
A First-In-Human (FIH) Phase 1/2 Study To Assess Safety, Tolerability, And Preliminary Anti-Tumor Activity Of REGN7945, An Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, In C
A First-In-Human (FIH) Phase 1/2 Study To Assess Safety, Tolerability, And Preliminary Anti-Tumor Activity Of REGN7945, An Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, In C
/
Reducing the frequency of outpatient review in people with cystic fibrosis on high-efficacy modulator therapy – a non-inferiority, randomised controlled trial (REFORM) (ACTRN12624000696594)
Reducing the frequency of outpatient review in people with cystic fibrosis on high-efficacy modulator therapy – a non-inferiority, randomised controlled trial (REFORM) (ACTRN12624000696594)
/
A Dose Adjusted, Open Label, Multi-Centre Study to Determine the Safety, Tolerability and Pharmacokinetics of STC3141 Administered as an Infusion forup to 72 hours in Subjects with Sepsis and Nor
A Dose Adjusted, Open Label, Multi-Centre Study to Determine the Safety, Tolerability and Pharmacokinetics of STC3141 Administered as an Infusion forup to 72 hours in Subjects with Sepsis and Nor
/
REDEEM: A randomised controlled trial of VV ECMO to de-sedate, extubate, and mobilise in hypoxic respiratory failure. (NCT05562505)
REDEEM: A randomised controlled trial of VV ECMO to de-sedate, extubate, and mobilise in hypoxic respiratory failure. (NCT05562505)
/
Recovery-focused Community support to Avoid readmissions and improve participation after Stroke (ACTRN12618001468213)
Recovery-focused Community support to Avoid readmissions and improve participation after Stroke (ACTRN12618001468213)
/
A Randomised Clinical Trial of a digital Self-Management package for people with Interstitial Lung Disease (ACTRN12623001133628)
A Randomised Clinical Trial of a digital Self-Management package for people with Interstitial Lung Disease (ACTRN12623001133628)
/